Recovery ⏱ Half-life: Short. Experimental

Vesugen

Vesugen (KED Peptide)

Updated March 15, 2026

Evidence at a Glance

Regulatory statusExperimental
Khavinson Lys-Glu-Asp (KED) vascular bioregulator; not an approved drug; Russian preclinical/clinical reports only
Human evidenceAnecdotal only
Animal evidenceLimited

A synthetic KED tripeptide in Khavinson's bioregulator family whose vascular claims trace almost entirely to Khavinson-affiliated Russian research and remain unreplicated.

What the research does not support

  • It is not an approved therapy for atherosclerosis, cardiovascular disease, or peripheral vascular disease.
  • Its claimed DNA/chromatin epigenetic action lacks independent Western in vitro or clinical confirmation.
  • Existing Russian clinical reports do not meet modern randomized-controlled-trial standards.
  • It is not shown to reverse vascular aging or repair endothelium in humans.
Half-Life
Short.
Mol. Weight
~390 g/mol

What is Vesugen?

Vesugen is a synthetic tripeptide designed to support vascular endothelial function and microcirculation.

Research Applications

Endothelial function, vascular aging, microcirculation support, and cardiovascular research.

Dosage Information (Research Use)

10-20 mg/day for 10-30 day courses. Research use only.

Reconstitution & Handling

Standard.

Half-Life & Pharmacokinetics

Short.

Reported Observations in Literature

Generally well-tolerated.

Key Research References

  • Khavinson VK, et al. “Short peptides modulate the effect of endonucleases.” Bull Exp Biol Med. 2006

How Vesugen Works

Vesugen modulates gene expression in endothelial cells, supporting vascular integrity and microcirculation.

Research Findings

Studied for cardiovascular aging, endothelial dysfunction, and microvascular health.

Dosage & Administration

10-20 mg/day for 10-30 day courses. Research use only.

Safety & Side Effects

Generally well-tolerated.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Lys-Glu-Asp
Molecular Weight ~390 g/mol
Half-Life Short.
Available Sizes 5mg
Storage Lyophilized: -20°C.

Key Research References

  • Khavinson VK, et al. "Short peptides modulate the effect of endonucleases." Bull Exp Biol Med. 2006

Related Peptides

View all →
Bronchogen
Recovery
Short peptide bioregulator researched for bronchial tissue support and respiratory epithelial recovery.
View Profile →
Abaloparatide
Recovery
FDA-approved synthetic analog of PTHrP that promotes bone formation and reduces fracture risk in postmenopausal osteoporosis.
View Profile →
KLOW
Recovery
KLOW is not a single compound. It is a trade name for a research blend of four peptides,…
View Profile → Buy Now